VivoSim Labs, INC. (VIVS) · Oct 16, 2026 · Material agreement
$86k rent abatement — $86,145.70 total abated rent; 2,892 sq. ft. surrendered
VivoSim Labs’ lease amendment gives up 2,892 square feet, reduces overhead, and extends its remaining San Diego lease through April 2028.
VivoSim is an early-stage pharmaceutical-services company commercializing 3D human liver and intestine tissue models for preclinical drug testing, rather than pursuing its former drug-development strategy. The filing is mainly a footprint-right-sizing move. VivoSim will surrender the 2,892-square-foot Suite 202 and retain only the 8,051-square-foot Suite 100, reducing its leased premises from approximately 10,943 square feet. 〔0〕 That points to tighter infrastructure needs or cost discipline while the company builds its services business—not expansion of operating capacity.
| Lease item | Filing terms |
|---|---|
| Existing premises | 10,943 sq. ft. (Lease premises) |
| Suite 202 surrendered | 2,892 sq. ft. (Lease premises) |
| Remaining Suite 100 | 8,051 sq. ft. (Lease premises) |
| Extended lease term | March 1, 2027–April 30, 2028 (Extended Lease Term) |
| Monthly base rent | $43,072.85 (Base Rent) |
| Monthly rent abatement | $21,536.43, March–June 2027 (Rental Abatement) |
| Total rent abatement | $86,145.70 (Rental Abatement) |
| Letter-of-credit security | $143,359.00, unchanged (Letter of Credit) |
The financial effect is modest but directionally helpful. The company receives four months of 50% base-rent relief totaling $86,145.70, while its share of building and project expenses also falls to 30.36% and 6.14%, respectively. 〔1〕 The filing does not provide the prior rent or total occupancy-cost savings, so the full cash benefit cannot be quantified.
The extension preserves operating continuity but does not signal acceleration. Suite 100 remains leased through April 30, 2028, with no further extension right, no tenant-improvement allowance, and the existing $143,359 letter of credit left unchanged. 〔2〕 That is supportive for near-term execution of the NAM-services strategy, but the smaller footprint and fixed end date make this a cost-control and consolidation event, not a growth milestone.
Bottom line: VivoSim is buying lower occupancy costs and roughly 18 months of facility continuity by giving up excess space. It modestly improves financial flexibility, but the downsizing also confirms a leaner operating posture rather than a new expansion signal.
Suite 202 surrender deadline, February 28, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!